ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 101 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $68,000 | -19.0% | 11,320 | 0.0% | 0.00% | -33.3% |
| Q4 2018 | $84,000 | -48.8% | 11,320 | 0.0% | 0.00% | -40.0% |
| Q3 2018 | $164,000 | -92.3% | 11,320 | -89.4% | 0.01% | -93.1% |
| Q2 2018 | $2,133,000 | +14.0% | 106,820 | 0.0% | 0.07% | 0.0% |
| Q1 2018 | $1,871,000 | -29.1% | 106,820 | -0.2% | 0.07% | -37.4% |
| Q4 2017 | $2,639,000 | +1.3% | 107,020 | +6.0% | 0.12% | -10.9% |
| Q3 2017 | $2,606,000 | +1.6% | 100,960 | +6.8% | 0.13% | -17.3% |
| Q2 2017 | $2,564,000 | -5.2% | 94,560 | +4.3% | 0.16% | -11.4% |
| Q1 2017 | $2,705,000 | +5.8% | 90,700 | -3.7% | 0.18% | -20.0% |
| Q4 2016 | $2,557,000 | – | 94,200 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |